AR026293A1 - Formas polimorficas de hidrocloruro de sertralina - Google Patents

Formas polimorficas de hidrocloruro de sertralina

Info

Publication number
AR026293A1
AR026293A1 ARP000105711A ARP000105711A AR026293A1 AR 026293 A1 AR026293 A1 AR 026293A1 AR P000105711 A ARP000105711 A AR P000105711A AR P000105711 A ARP000105711 A AR P000105711A AR 026293 A1 AR026293 A1 AR 026293A1
Authority
AR
Argentina
Prior art keywords
sertraline hydrochloride
polymorphic forms
polymorphic
forms
preparation
Prior art date
Application number
ARP000105711A
Other languages
English (en)
Original Assignee
Ciba Sc Holding Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8243113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR026293(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ciba Sc Holding Ag filed Critical Ciba Sc Holding Ag
Publication of AR026293A1 publication Critical patent/AR026293A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se descubrio una forma cristalina de hidrocloruro de sertralina, referida de ahora en más como forma polimorfica CSC2, que tiene una velocidad dedisolucion que aumentará sorprendentemente la velocidad de absorcion de una droga. Más aun, se describen las diferentes formas cristalinas de los solvatosalcoholicos de hidrocloruro de sertralina, las formas cristalinas de los hidratos de hidrocloruro de sertralina, referidas de ahora en más como formapolimorfica CSC1, un proceso para la preparacion de la forma amorfa del hidrocloruro de sertralina, y diferentes procesos para la preparacion de las formaspolimorficas I, II, V y T1.
ARP000105711A 1999-10-29 2000-10-27 Formas polimorficas de hidrocloruro de sertralina AR026293A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99810981 1999-10-29

Publications (1)

Publication Number Publication Date
AR026293A1 true AR026293A1 (es) 2003-02-05

Family

ID=8243113

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000105711A AR026293A1 (es) 1999-10-29 2000-10-27 Formas polimorficas de hidrocloruro de sertralina

Country Status (17)

Country Link
US (2) US6872853B1 (es)
EP (1) EP1224160B1 (es)
JP (1) JP2003513062A (es)
CN (1) CN1384816A (es)
AR (1) AR026293A1 (es)
AT (1) ATE409684T1 (es)
AU (1) AU1386301A (es)
CA (1) CA2387135A1 (es)
DE (1) DE60040406D1 (es)
HU (1) HUP0203559A3 (es)
IL (2) IL149050A0 (es)
MX (1) MXPA02004255A (es)
MY (1) MY141509A (es)
TR (1) TR200201146T2 (es)
TW (1) TWI260315B (es)
WO (1) WO2001032601A1 (es)
ZA (1) ZA200203254B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69929462T2 (de) * 1998-11-27 2006-09-07 Teva Pharmaceutical Industries Ltd. Sertralin hydrochlorid form
US6500987B1 (en) * 1998-11-27 2002-12-31 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
EP1632475A1 (en) * 1998-11-27 2006-03-08 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
US6495721B1 (en) 1999-08-09 2002-12-17 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride Form II and methods for the preparation thereof
US20050119351A1 (en) * 1999-10-29 2005-06-02 Van Der Schaaf Paul A. Polymorphic forms of sertraline hydrochloride
US7442838B2 (en) * 1999-10-29 2008-10-28 Ciba Specialty Chemicals Corp. Polymorphic forms of sertraline hydrochloride
EP1774965A3 (en) * 1999-12-21 2007-10-10 Teva Pharmaceutical Industries Ltd Novel sertraline hydrochloride polymorph, processes for preparing them, compositions containing them and methods of using them
KR100791872B1 (ko) 1999-12-21 2008-01-07 테바 파마슈티컬 인더스트리즈 리미티드 신규 서트랄린 염산염 다형, 그것의 제조 방법, 그것을 함유하는 조성물, 및 그것을 사용하는 방법
IN192343B (es) * 2000-05-26 2004-04-10 Ranbaxy Lab Ltd
WO2002096859A1 (en) * 2001-05-31 2002-12-05 Orion Corporation Fermion Process for preparing sertraline hydrochloride polymorphic form ii
AU2003251290A1 (en) * 2002-04-29 2003-11-17 Teva Pharmaceutical Industries Ltd. Process for preparation of polymorphic form ii of sertraline hydrochloride, pharmaceutical formulations and methods of administration thereof
EP1527617A4 (en) * 2002-06-27 2006-01-04 Interdigital Tech Corp PAIR EXCHANGE TO PAIR USER EQUIPMENT MEASUREMENT INFORMATION BETWEEN RADIO NETWORK CONTROLLERS
JP2007502329A (ja) * 2003-05-23 2007-02-08 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド セルトラリン組成物
JP4791970B2 (ja) 2003-11-04 2011-10-12 シプラ・リミテッド 選択的セロトニン再取込み阻害剤の多形体の製造方法
EP1711493A2 (en) * 2004-02-06 2006-10-18 CIBA SPECIALTY CHEMICALS HOLDING INC. Patent Departement Crystalline forms of zolmitriptan
EP1893559A2 (en) * 2005-06-09 2008-03-05 Teva Pharmaceutical Industries Ltd Process for preparation of sertraline hydrochloride form i
US7518019B2 (en) 2006-06-01 2009-04-14 Hetero Drugs Limited Processes for preparing sertraline hydrochloride crystalline forms
CA2594198A1 (en) * 2007-07-20 2009-01-20 Apotex Pharmachem Inc. A novel process for the preparation of sertraline hydrochloride form ii
US9186642B2 (en) 2010-04-28 2015-11-17 The Procter & Gamble Company Delivery particle
US9993793B2 (en) 2010-04-28 2018-06-12 The Procter & Gamble Company Delivery particles
WO2012138696A2 (en) 2011-04-07 2012-10-11 The Procter & Gamble Company Shampoo compositions with increased deposition of polyacrylate microcapsules
CN103458871B (zh) 2011-04-07 2015-05-13 宝洁公司 具有增强的聚丙烯酸酯微胶囊的沉积的调理剂组合物
WO2012138710A2 (en) 2011-04-07 2012-10-11 The Procter & Gamble Company Personal cleansing compositions with increased deposition of polyacrylate microcapsules
CN105061217A (zh) * 2015-06-30 2015-11-18 徐静 枸橼酸舍曲林的2种晶型及其制备方法
CN112552188B (zh) * 2020-12-17 2023-07-28 山西仟源医药集团股份有限公司 盐酸舍曲林晶型i的制备方法
CN113588626B (zh) * 2021-08-24 2024-05-24 上海师范大学 一种苯丙氨酸对映体的拉曼光谱检测方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536518A (en) 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US5082970A (en) 1991-03-06 1992-01-21 Pfizer Inc. Process for recycling amine isomer
GB9114947D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline
US5248699A (en) 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
US5734083A (en) * 1996-05-17 1998-03-31 Torcan Chemical Ltd. Sertraline polymorph
HU222341B1 (hu) 1996-12-18 2003-06-28 Richter Gedeon Vegyészeti Gyár Rt. Eljárás sertralin előállítására és az eljárásban alkalmazott intermedier
DE69713353D1 (de) * 1997-12-11 2002-07-18 Torcan Chemical Ltd Sertralin-Polymorph mit verbesserter Wasserlöslichkeit
ES2217748T3 (es) 1998-03-18 2004-11-01 Ciba Specialty Chemicals Holding Inc. Procedimiento para la hidrogenacin catalitica cis-selectiva de ciclohexilidenaminas.
JP2000026378A (ja) 1998-07-03 2000-01-25 Sumika Fine Chemicals Co Ltd 塩酸セルトラリンの製法
DE69929462T2 (de) 1998-11-27 2006-09-07 Teva Pharmaceutical Industries Ltd. Sertralin hydrochlorid form
US6500987B1 (en) 1998-11-27 2002-12-31 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
US6495721B1 (en) 1999-08-09 2002-12-17 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride Form II and methods for the preparation thereof
KR100791872B1 (ko) 1999-12-21 2008-01-07 테바 파마슈티컬 인더스트리즈 리미티드 신규 서트랄린 염산염 다형, 그것의 제조 방법, 그것을 함유하는 조성물, 및 그것을 사용하는 방법

Also Published As

Publication number Publication date
DE60040406D1 (de) 2008-11-13
US6939992B2 (en) 2005-09-06
US20040132828A1 (en) 2004-07-08
CA2387135A1 (en) 2001-05-10
ZA200203254B (en) 2003-07-22
HUP0203559A3 (en) 2008-01-28
US6872853B1 (en) 2005-03-29
IL149050A (en) 2007-03-08
MXPA02004255A (es) 2002-10-17
TR200201146T2 (tr) 2004-12-21
HUP0203559A2 (hu) 2003-03-28
JP2003513062A (ja) 2003-04-08
MY141509A (en) 2010-05-14
IL149050A0 (en) 2002-11-10
TWI260315B (en) 2006-08-21
ATE409684T1 (de) 2008-10-15
EP1224160A1 (en) 2002-07-24
CN1384816A (zh) 2002-12-11
EP1224160B1 (en) 2008-10-01
WO2001032601A1 (en) 2001-05-10
AU1386301A (en) 2001-05-14

Similar Documents

Publication Publication Date Title
AR026293A1 (es) Formas polimorficas de hidrocloruro de sertralina
ECSP056020A (es) Inhibidores del factor inhibidor de la migración de los macrofagos y metodos para su identificacion
CO2021016594A2 (es) Pirroles tricíclicos condensados como moduladores de alfa-1 antitripsina
AR071788A1 (es) Derivados de 3-aminocarbazol, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos para tratar y/o prevenir trastornos asociados con la produccion de prostaglandina e2(pge2), tales como aterosclerosis, artritis, artrosis y tumores, entre otros.
CL2020002698A1 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
UY27304A1 (es) Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
CL2021002137A1 (es) Compuestos de tioeno[3,2-b] piridin-7-amina para tratar la disautonomía familiar.
CL2011002460A1 (es) Torta liofilizada que comprende un inhibidor de proteasoma derivado del acido protonico, una ciclodextrina, y al menos un agente espesante y/o un surfactante; metodo para su fabricacion; y su uso en el tratamiento de mieloma multiple.
CL2012003125A1 (es) Metodo para eliminar microbios de las manos que comprende una composicion farmaceutica que comprende povidona yodada, una amida terciaria, aceite de coco, al menos un tensioactivo y agua; composicion farmaceutica.
CO6321225A2 (es) Particulas portadoras sólidas para mejorar la procesabilidad de un agente farmacéutico
UY26886A1 (es) Polimorfos de un análogo de epotilona
IL183244A0 (en) Process for the preparation of 1-amino-3,5-dimethyladamantane hydrochloride
CR6616A (es) Nuevos derivados de biarileter utiles como inhibidores de la recaptacion de monoaminas
ECSP078055A (es) Formas sólidas cristalinas de tigeciclina y métodos para preparar las mismas
CR8778A (es) Revestimientos de azucar y metodos para estos
UY29320A1 (es) 18-metil-19-nor-17-pregn-4-en-21, 17-carbolactonas, así como preparaciones farmacéuticas que las contienen
CR6436A (es) Inhibidores de la receptacion de monoaminas para el tratamiento de trastornos del snc
PA8587101A1 (es) Nuevos derivados de dihidropirimido [4,5-d] pirimidinona sustituida por amiino, fabricacion y uso de los mismos como agentes farmaceuticos
CL2013000063A1 (es) Un método para tratar a un sujeto que comprende administrar n-etil-n-fenil1,2-dihidroxi-4-hodroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida opcionalmente deuterada, para el tratamiento de una enfermedad autoinmunitaria; una mezcla de los mismos; composición farmaceutica y su proceso de preparacion.
CL2019003258A1 (es) Composiciones y compuestos terapéuticos y métodos para utilizarlos.
AR024998A1 (es) Nuevos retinoides para el tratamiento del enfisema
CO6551754A2 (es) 7-[3.5-dihidroxi-2-(3-hidrixi-5-fenil-pent-1-enil)- ciclopentil] -n-etil-hept-5-enamida(bimatoprost) en forma cristalina ii, mètodos para la preparaciòn y mètodo para su uso
BR0212807A (pt) Processo para a preparação de formas de dosagem de dissolução rápida
UY27410A1 (es) Formas novedosas crudas cristalinas
PA8591901A1 (es) Derivados de 3h-quinazolin-4-ona como inhibidores de mao-b

Legal Events

Date Code Title Description
FA Abandonment or withdrawal